STAT, October 20, 2017
Ed Silverman


Read the Full Article

For the fourth time this month, U.K. authorities have opened a new investigation into an unspecified number of drug makers over potential violations of anti-competitive laws concerning generic drugs.

The U.K. Competition and Markets Authority opened the probes into “various parties” regarding “suspected abuse” into “certain generic” medicines, according to statements on the agency web site. The latest probe was opened on Wednesday, while the other three investigations began on Oct. 10. Further details were not disclosed. [...]

health care finance health law policy international pharmaceuticals regulation